PUBLIC COMPANY
saveMassachusetts General Hospital
updated 4mo ago
Massachusetts General Hospital is a teaching hospital located in the West End neighborhood of Boston, Massachusetts. It is the original and largest clinical education and research facility of Harvard Medical School/Harvard University, and houses the world's largest hospital-based research program with an annual research budget of more than $1.2 billion in 2021. It is the third-oldest general hospital in the United States with a patient capacity of 999 beds.
community read0 votes
🐶 often sniffed alongside
top 8- tagPulmonology8 co-mentions · 6 sources
- tagPain3 co-mentions · 2 sources
- tagMonoclonal Antibody2 co-mentions · 2 sources
- tagType 2 Diabetes2 co-mentions · 1 sources
- tagAlzheimer's Disease2 co-mentions · 2 sources
- drugAlzheimer's Disease2 co-mentions · 2 sources
- tagOncology2 co-mentions · 2 sources
- tagOphthalmology1 co-mentions · 1 sources
pipeline
1
marketed
0
phase 3
0
catalysts ytd
48
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Preclinical
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1AZD6738 for Patients With Progressive MDS or CMML
- phase2Delayed Tolerance Through Mixed Chimerism
- phase4Delayed-Release, Extended-Release Methylphenidate (Jornay PM) for Adolescents and Young Adults With ADHD and Cannabis Use Disorder
- phase1Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
- phase2Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission
- phase2Teclistamab In Waldenstrom's Macroglobulinemia
- N/APrevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
- —Biomechanical Precision Medicine Registry for Patients With and Without Heart Failure
🐶 Hiring Signal
News
- US to grant up to $125M for personalized RNA manufacturing innovationA new program from ARPA-H has devoted funding to make individualized RNA-based genetic medicine more efficient to produce and improve accessibility.biospace · 1mo ago
- Capricor, Replimune illustrate why FDA must listen to rare disease specialistsLast month’s FDA advisory committee meetings for therapies developed by Capricor Therapeutics and Replimune effectively illustrate the different outcomes for patients when the agency prioritizes sp…biospace · 1mo ago
- CDC releases latest life expectancy dataDeleted public comments on White House proposals, how Trump cuts are reshaping rural health care, and more Morning Rounds newsstat · 1mo ago
- Replimune’s twice-rejected melanoma drug prevails in FDA adcommFollowing a pair of FDA rejections of its melanoma drug, Replimune’s fortunes flipped today after an advisory committee voted 10 to 3 in favor of the candidate’s effectiveness.fiercebiotech · 2mo ago
- After PCOS became PMOS, there’s hope for new awareness among Black and Latina womenGrowing awareness of a painful endocrine disorder now named PMOS is good news for women of color, who have high prevalence and low diagnosis.stat · 2mo ago
- Study of Yescarta patients reveals genetic red flags for CAR-T therapy side effectsA new analysis of patients who took part in clinical trials for Kite Pharma’s CAR-T cell therapy Yescarta has revealed genetic signatures of toxicity risk, potentially providing a path forward for…fiercebiotech · 2mo ago
- Opinion: Your grandparents are using cannabis. Doctors can help them do it safelyOver the past 25 years, I have treated thousands of medical cannabis patients with extremely few ill effects, one doctor writes.stat · 2mo ago
- Major readouts from the annual diabetes conferenceWhy "Schedule F" matters, the Ebola outbreak response, and more health news from Morning Roundsstat · 3mo ago
- When it’s time to save a limb, novel clinic meets unhoused people where they areUnmet vascular needs can lead to limb loss among unhoused patients. An unusual Massachusetts General Hospital program meets patients where they are.stat · 3mo ago
- Dr Parikh on the Feasibility and Importance of Immunotherapy Trials in Anal CancerAparna R. Parikh, MD, discusses how trials like PODIUM-303 are reshaping the treatment paradigm for squamous cell anal carcinomas.onclive · 4mo ago
comments(0)
5-min edit window · permanent after that